Skip to main content
. 2017 Nov 22;29(6):847–858. doi: 10.1007/s00192-017-3512-3

Table 2.

Characteristics of responders versus nonresponders (women lost to follow-up)

Responders (n 127) Lost to follow-up (n 63) Difference (95% CI)
Age at time of surgery (years) 61.6 ± 9.7 67.7 ± 10.4 −6.1* (−9.2, −3.1)
Parity 2 (1–6) 3 (0–5) 0 (0, 1.0)
BMI (kg/m2) 26.6 ± 4.2 26.9 ± 4.1 −0.3 (−1.6, 1.1)
Prior number of POP surgeries 1 (1–3) 1 (1–2) 0 (0, 0)
Prior number of treated vaginal compartments 2 (1–3) 2 (1–3) 0 (0, 0)
POP-Q stage at time of surgery
• Stage II 69 (54.3) 21 (33.3) 21.0* (6.5, 35.5)
• Stage III 55 (43.3) 42 (66.7) −23.4* (−37.8, −8.9)
• Stage IV 3 (2.4) 0 2.4 (−0.3, 5.0)
Pain at baseline
• Yes 61/113 (54.0) 23/48 (47.9) 6.1 (−10.8, 22.9)
• UDI pain score 28.7 (26.9, 30.4) 23.4 (19.8, 27.0) 5.3 (−3.7, 14.3)
Dyspareunia at baseline
• Moderately to quite a bit 26/111 (23.4) 3/45 (6.7) 16.8* (6.0, 27.5)
• Yes 45/111 (40.5) 4/45 (8.9) 31.7* (19.3, 44.0)
Outcomes at 1-year follow-up
Composite success 83/111 (74.8) 31/43 (72.1) 2.6 (−12.9, 18.3)
Overall POP-Q ≥ stage II 66/115 (57.4) 23/52 (44.2) 13.2 (−3.1, 29.4)
PGI-I (much to very much better) 78/108 (72.2) 31/49 (63.3) 8.9 (−6.9, 24.9)
VAS EQ-5D 78.2 ± 14.6 72.4 ± 20.3 5.8* (0.2, 11.5)
Exposure 9/114 (7.9) 5/52 (9.6) −1.7 (−11.1, 7.7)
UDI pain score 14.3 (13.1, 15.5) 13.8 (10.4, 17.1) 0.5 (−6.9, 7.9)
Dyspareunia
• Moderately to quite a bit 18/115 (16.2) 3/47 (4.7) 9.3 (−0.4, 18.9)
• Yes 35/115 (30.4) 8/46 (17.4) 13.0 (−0.8, 26.9)

Data presented as mean ±  standard deviation (SD), median (range), n (%), or mean (95% CI)

BMI body mass index, PGI-I Patient Global Impression of Improvement, VAS EQ-5D perceived health condition according visual analog scale, EuroQuol-5D questionnaire (100 = best imaginable, 0 = worst imaginable), UDI pain score urodynamic pain score, 0–100, CI confidence interval

*This difference would be statistically significant if tested at a significance level of 0.05